These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 23006540

  • 1. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 3. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 5. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ, Chubb BD, Smith IC, Valentine WJ.
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Mar; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ, Tucker DM.
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ.
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM, Schultz NM, Lee TA.
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [Abstract] [Full Text] [Related]

  • 20. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X, Vondeling H.
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.